Fuliang Chu, Ph.D.
Department of Lymphoma - Myeloma, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Lymphoma - Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Lymphoma/Myeloma - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Instructor, Lymphoma/Myeloma - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2007 | Institute of Microbiology, Chinese Academy of Sciences, Beijing, CN, Ph.D. in Biochemistry |
| 2004 | Academy of Military Medical Sciences, Beijing, CN, MA in Pathology and Physiopathology |
| 1995 | Xuzhou Normal University, Xuzhou, CN, BA in Biology |
Postgraduate Training
| 2008-2012 | Research Fellowship, The University of Texas M. D. Anderson Cancer Center, Houston, Texas |
| 2008-2008 | Research Fellowship, National Institute of Biological Sciences, Beijing |
Experience & Service
Faculty Academic Appointments
Not specified, Lymphoma/Myeloma - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2018
Not specified, Lymphoma/Myeloma - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2012
Not specified, National Institute of Biological Sciences, Beijing, 2008 - 2008
Administrative Appointments/Responsibilities
Biological Teacher, No. 11 Middle School of Xuzhou, Xuzhou, 1995 - 2001
Editorial Activities
Co-Editor, Contemporary Oncology, 2016 - Present
Editor and Reviewer, Journal of Leukemia & Lymphoma (Chinese), 2010 - Present
Honors & Awards
| 2012 | American Society of Hematology Abstract Achievement Award (2012), ASH |
| 2011 | Margaret L. Kripke Award for Outstanding Tumor Immunologist, CCIR, MD Anderson Cancer Center |
| 2010 | Bristol-Myers Squibb Award for Clinical/Translational Research,(2010), MD Anderson Cancer Center |
| 2009 | American Society of Hematology Travel Award (2009), ASH |
| 2007 | Scholarship of President of Chinese Academy of Sciences (2007), Chinese Academy of Sciences |
| 2007 | Excellent Graduated Student of Graduate University (2007), Chinese Academy of Sciences |
| 2005 - 2007 | Scholarship of Institute of Microbiology,CAS, Institute of Microbiology, Chinese Academy of Sciences |
| 2005 | Scholarship of General Director, Institute of Microbiology, Chinese Academy of Sciences |
| 2001 - 2004 | Best MA Thesis of (2004), Academy of Military Medical Sciences (AMMS) |
Professional Memberships
Grant & Contract Support
| Date: | 2024 - 2028 |
| Title: | CD79b-targeting CAR T-cell therapy for B-cell lymphomas |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | CO-I |
| Date: | 2023 - 2025 |
| Title: | Biology and therapeutic targeting of transformed follicular lymphoma |
| Funding Source: | Jaime Erin Follicular Lymphoma Research Consortium |
| Role: | CO-I |
| ID: | IFLI 000010 |
| Date: | 2019 - 2023 |
| Title: | CD79b as a novel target for CAR T-cell therapy in B-cell malignancies |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | CO-I |
| ID: | 6591-20 |
| Date: | 2019 - 2020 |
| Title: | Anti-CD79b chimeric antigen receptor (CAR) T-cell therapy for B-cell malignancies |
| Funding Source: | MD Anderson Cancer Center IRG |
| Role: | PI |
| Date: | 2016 - 2019 |
| Title: | Preclinical and Human Correlative Studies of a Novel Bruton Tyrosine Kinase Inhibitor in Pancreatic Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | CO-I |
| ID: | CA150626 |
| Date: | 2015 - 2019 |
| Title: | effort Correlative studies for the phase I trial of KA2237 in B-cell malignancies |
| Funding Source: | Karus Therapeutics |
| Role: | CO-I |
| Date: | 2015 - 2018 |
| Title: | Correlative studies for phase 2 trial of ACP-196 + Pembrolizumab in advanced or metastatic pancreatic cancer |
| Funding Source: | Acerta Pharma |
| Role: | CO-I |
| Date: | 2015 - 2017 |
| Title: | Biomarkers for anti-PD-1 antibody therapy in follicular lymphoma |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | CO-I |
| ID: | P-QFC-3068-14 |
| Date: | 2014 - 2018 |
| Title: | Correlative Studies for the Phase 2 trial of Nivolumab in relapsed/refractory follicular lymphoma |
| Funding Source: | Bristol-Myers Squibb |
| Role: | CO-I |
| ID: | CA209-140 |
| Date: | 2014 - 2018 |
| Title: | Correlative Studies for the Phase 2 trial of Nivolumab in relapsed/refractory diffuse large B-cell lymphoma |
| Funding Source: | Bristol-Myers Squibb |
| Role: | CO-I |
| ID: | CA209-139 |
| Date: | 2014 - 2024 |
| Title: | Project 1: Improving Efficacy and affordability of CAR T-cell therapy for lymphoma |
| Funding Source: | B-cell Lymphoma Moon Shot |
| Role: | CO-I |
| Date: | 2014 - 2018 |
| Title: | Flagship Project 3: Personalized Immunotherapy for B-cell Lymphoma |
| Funding Source: | MDACC Moon Shot Program |
| Role: | CO-I |
| Date: | 2014 - 2016 |
| Title: | Correlative Studies for the Phase 2 trial of Ibrutinib in previously untreated FL |
| Funding Source: | Pharmacyclics, Inc |
| Role: | CO-I |
| ID: | 12543 |
| Date: | 2012 - 2014 |
| Title: | Pro and Anti-Tumor Function of Regulatory T cells in Human Follicular Lymphoma |
| Funding Source: | Lymphoma Research Foundation |
| Role: | PI |
| Date: | 2011 - 2016 |
| Title: | Predictors of clinical outcome after therapeutic vaccination in follicular lymphoma |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | R01CA155143 |
| Date: | 2010 - 2014 |
| Title: | Role of monocytes in immunopathology in human follicular lymphoma |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | CO-I |
| ID: | 50792 |
| Date: | 2010 - 2011 |
| Title: | Enhancing antitumor immunity with anti-PD-1 antibody in follicular lymphoma |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | R21CA143785 |
| Date: | 2008 - 2011 |
| Title: | Immunosuppression in lymphoma tumor microenvironment |
| Funding Source: | Doris Duke Charitable Foundation |
| Role: | CO-I |
Selected Publications
Peer-Reviewed Articles
- Liu, S, Xie, SM, Liu, W, Gagea Iurascu, M, Hanker, AB, Nguyen, N, Singareeka Raghavendra, A, Yang-Kolodji, G, Chu, F, Neelapu, SS, Marchese, A, Hanash, S, Zimmermann, J, Arteaga, CL, Tripathy, D. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Breast Cancer Research 25(1), 2023. e-Pub 2023. PMID: 37280713.
- Chu F, Cao J, Liu J, Yang H, Davis TJ, Kuang SQ, Cheng X, Karri S, Vien LT, Bover L, Sun R, Vega F, Green M, Davis RE, Neelapu SS. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas. Journal for ImmunoTherapy for Cancer 11(11):e007515, 2023. e-Pub 2023. PMID: 38007239.
- Nastoupil LJ, Chin CK, Westin JR, Fowler NH, Samaniego F, Cheng X, Ma MCJ, Wang Z, Chu F, Dsouza L, Obi C, Mims J, Feng L, Zhou S, Green M, Davis RE, Neelapu SS. Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. Blood Adv 6(4):1143-1151, 2022. e-Pub 2022. PMID: 35015819.
- Plaks V, Rossi JM, Chou J, Wang L, Poddar S, Han G, Wang Z, Kuang SQ, Chu F, Davis RE, Vega F, Bashir Z, Jacobson CA, Locke FL, Reagan PM, Rodig SJ, Lekakis LJ, Flinn IW, Miklos DB, Bot A, Neelapu SS. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood 138(12):1081-1085, 2021. e-Pub 2021. PMID: 34041526.
- Chu F, Li HS, Liu X, Cao J, Ma W, Ma Y, Weng J, Zhu Z, Cheng X, Wang Z, Liu J, Jiang ZY, Luong AU, Peng W, Wang J, Balakrishnan K, Yee C, Dong C, Davis RE, Watowich SS, Neelapu SS. CXCR5+CD8+ T cells are a distinct functional subset with an antitumor activity. Leukemia 33(11):2640-2653, 2019. e-Pub 2019. PMID: 31028278.
- Chu F, Cao J, Neelalpu SS. Versatile CAR T-cells for cancer immunotherapy. Contemp Oncol (Pozn) 22(1A):73-80, 2018. e-Pub 2018. PMID: 29628798.
- Mao F, Tu Q, Wang L, Chu F, Li X, Li HS, Xu W. Mesenchymal Stem Cells and Their Therapeutic Applications in Inflammatory Bowel Disease. Oncotarget 23:38008-38021, 2017. e-Pub 2017.
- Li HS, Liu C, Xiao Y, Chu F, Liang X, Peng W, Hu J, Neelapu SS, Sun SC, Hwu P, Watowich SS. Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells. Sci Signal 9(447):ra94, 2016. e-Pub 2016. PMID: 27678219.
- Weng J, Moriarty KE, Baio FE, Chu F, Kim SD, He J, Jie Z, Xie X, Ma W, Qian J, Zhang L, Yang J, Yi Q, Neelapu SS, Kwak LW. IL-15 enhances the antitumor effect of human antigen-specific CD8(+) T cells by cellular senescence delay. Oncoimmunology 5(12):e1237327, 2016. e-Pub 2016. PMID: 28123872.
- Voo KS, Foglietta M, Percivalle E, Chu F, Nattamai D, Harline M, Lee ST, Bover L, Lin HY, Baladandayuthapani V, Delgado D, Luong A, Davis RE, Kwak LW, Liu YJ, Neelapu SS. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer 135(12):2834-46, 2014. e-Pub 2014. PMID: 24771328.
- Liu X, Chen X, Zhong B, Wang A, Wang X, Chu F, Nurieva RI, Yan X, Chen P, van der Flier LG, Nakatsukasa H, Neelapu SS, Chen W, Clevers H, Tian Q, Qi H, Wei L, Dong C. Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development. Nature 507(7493):513-8, 2014. e-Pub 2014. PMID: 24463518.
- Chu F, Neelapu SS. Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets. Oncoimmunology 3(1):e28101, 2014. e-Pub 2014. PMID: 24808975.
- Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69-77, 2014. e-Pub 2014. PMID: 24332512.
- Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, Sharma R, Delgado D, Chou T, Lin HY, Baladandayuthapani V, Luong A, Vega F, Fowler N, Dong C, Davis RE, Neelapu SS. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J Immunol 190(12):6681-93, 2013. e-Pub 2013. PMID: 23686488.
- Weng J, Rawal S, Chu F, Park HJ, Sharma R, Delgado DA, Fayad L, Fanale M, Romaguera J, Luong A, Kwak LW, Neelapu SS. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood 120(8):1613-23, 2012. e-Pub 2012. PMID: 22645177.
- Chu F, Qin Y, Zheng Y. Highlight Latest Hematology Research and Clinical Care Breakthroughs from 53rd ASH Annual Meeting. Journal of Leukemia & Lymphoma 20:705-707, 2011. e-Pub 2011.
- Chung Y, Tanaka S, Chu F, Nurieva RI, Martinez GJ, Rawal S, Wang YH, Lim H, Reynolds JM, Zhou XH, Fan HM, Liu ZM, Neelapu SS, Dong C. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med 17(8):983-8, 2011. e-Pub 2011. PMID: 21785430.
- Jun L, Yeping S, Jinaxun Q, Fuliang C, Wu H, Feng G, Li T, Yan J, Gao GF. The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes. J Infect Dis 202:1171-1180, 2010. e-Pub 2010.
- Chen W, Gao F, Chu F, Zhang J, Gao GF, Xia C. Crystal structure of a bony fish beta2-microglobulin: insights into the evolutionary origin of immunoglobulin superfamily constant molecules. J Biol Chem 285(29):22505-12, 2010. e-Pub 2010. PMID: 20444690.
- Qian X, Qi J, Chu F, Liu J, Li Q, Yan J. Crystallization and preliminary X-ray analysis of the V domain of human nectin-2. Acta Crystallogr Sect F Struct Biol Cryst Commun 65:615-7, 2009. e-Pub 2009. PMID: 19478445.
- Chen Y, Gao F, Chu F, Peng H, Zong L, Liu Y, Tien P, Gao GF. Crystal structure of myeloid cell activating receptor leukocyte Ig-like receptor A2 (LILRA2/ILT1/LIR-7) domain swapped dimer: molecular basis for its non-binding to MHC complexes. J Mol Biol 386(3):841-53, 2009. e-Pub 2009. PMID: 19230061.
- Ya T, Zhang Q, Chu F, Merritt J, Bilige M, Sun T, Du R, Zhang H. Immunological evaluation of Lactobacillus casei Zhang: a newly isolated strain from koumiss in Inner Mongolia, China. BMC Immunol 9:68, 2008. e-Pub 2008. PMID: 19019236.
- Khan AH, Chu F, Feng Y, Zhang Q, Qi J, Gao GF. Crystallization and preliminary crystallographic analysis of recombinant immunoglobulin G-binding protein from Streptococcus suis. Acta Crystallogr Sect F Struct Biol Cryst Commun 64:757-9, 2008. e-Pub 2008. PMID: 18678951.
- Chen W, Chu F, Peng H, Zhang J, Qi J, Jiang F, Xia C, Gao F. Expression, purification, crystallization and preliminary X-ray diffraction analysis of grass carp beta2-microglobulin. Acta Crystallogr Sect F Struct Biol Cryst Commun 64:200-2, 2008. e-Pub 2008. PMID: 18323608.
- Chen* Y, Chu* F, Gao F, Zhou B, Gao GF. Stability Engineering and Biological Characterization of the Myeloid Activating Receptor Immunoglobulin-Like Transcript 1 (ILT1/LIR7). Protein Expr. and Purif 56:253-260, 2007. e-Pub 2007.
- Chu F, Lou Z, Wai CY, Liu Y, Gao B, Bell JI, F Gao ZRAG. First glimpse of the presentation of two immunogenic SIV epitopes by a rhesus monkey MHC class I molecule, Mamu-A*01: structural insights into CTL escape. The Journal of Immunology 178:944-952, 2007. e-Pub 2007.
- Xiao H, Chu F, Gao GF. AIV of Qinghai Lake. Infectious Diseases Information 18:172, 2005. e-Pub 2005.
- Fu-Sheng W, Fuliang C, Lei J, Yonggang L, Zheng Z, Dongping X, Ming S, Hao W, Moulds JM. Acquired but reversible loss of erythrocyte complement receptor 1 (CR1, CD35) and its longitudinal alteration in patients with severe acute respiratory syndrome. Clin Exp Immunol 139:112-119, 2005. e-Pub 2005.
- Dongping X, Zheng Z, Lei J, Fuliang C, Yuanli M, Wang H, Mingxu L, Min W, Lingxia Z, Wang Fu-Sheng GGFA. Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase. European Journal of Clinical Microbiology & Infectious Diseases 24:165-171, 2005. e-Pub 2005.
- Chu F, Lou Z, Gao B, Bell JI, F Gao ZRAG. Complex assembly, crystallization, and preliminary X-ray crystallographic studies of rhesus macaque MHC Mamu-A*01 complexed with an immunodominant SIV-Gag nonapeptide. Acta Crystallogr Sect F Struct Biol Cryst Commun 61:614-616, 2005. e-Pub 2005.
- Fuliang C, Fu-Sheng W, Dongping X, Lei J. Polymorphism and expression level of CD35 molecules on erythrocytes of SARS patients and its relation with disease progress. National Medical Journal of China 84:235-236, 2004. e-Pub 2004.
- Dongping X, Zheng Z, Yuanli M, Yonggang L, Bo W, Bingli C, Fuliang C, Xiaoqian C, Lingxia Z, Fu-sheng W. Dynamic analysis of anti-Cov antibody and SARS coronavirus in the plasma of 25 SARS patients. Medical Journal of Chinese People’s Liberation Army 29:415-417, 2004. e-Pub 2004.
- Dongping X, Zheng Z, Fuliang C, Yonggang L, Lei J, Lingxia Z, Fu G, Fu-Sheng W. Genetic Variation of SARS Coronavirus in Beijing Hospital. Emerging Infectious Diseases 10:789-794, 2004. e-Pub 2004.
- Chu Fuliang and Wang FS. Using FACS and in situ hybrid technology to detect virus in T lymphocytes of HIV-1 patients. Chinese Journal of AIDS and STD 10:321-323, 2004. e-Pub 2004.
- Zhenping F, Fu-Sheng W, Dongping X, Fuliang C, Ming S, Yueshu Z, Lingxia Z. Detection of HBcAg-specific cytotoxic lymphocytes and their association with clinical status in patients with hepatitis B. National Medical Journal of China 84:2073-2076, 2004. e-Pub 2004.
- Zheng Z, Dongping X, Fu-sheng W, Yonggang L, Hanwei L, Lei J, Fuliang C, Min W, Zirong T. Dynamic detection of RNA of SARS-associated coronavirus in blood and excreta of SARS patients. Medical Journal of Chinese People’s Liberation Army 29:418-420, 2004. e-Pub 2004.
- Zheng Z, Fu-sheng W, Min Z, Jingchao L, Dongping X, Lei J, Jumei C, Min W, Fuliang C. Characterization of peripheral dendritic cell subsets and its implication in patients infected with severe acute respiratory syndrome. National Medical Journal of China. 2004, 84:22-26 84:22-26, 2004. e-Pub 2004.
- Zheng Z, Dongping X, Yonggang L, Lei J, Fuliang C, Wang, Fu-Sheng. Variation Analysis of Nucleocapsid Gene of SARS Coronavirus Transmitted in Beijing Area. China Biotechnology 24:98-102, 2004. e-Pub 2004.
- Fuliang Chu and Wang FS. Progress in through coreceptors to inhibit HIV-1 infection and novel drug development. Chinese Journal of AIDS and STD 2:117-119, 2003. e-Pub 2003.
- Hong S, Fu-sheng W, Zhe W, Lei J, Fuliang C, Changqing W, Weiguo H, Weiguo C, Mingxu L. Polymorphism of mannose-binding protein alleles associated with human immunodef iciency virus-1 infection in Chinese Han and Uigur ethnic populations. . 2003, 9:8-11. Chinese Journal of AIDS and STD 9:8-11, 2003. e-Pub 2003.
- Fuliang Chu and Wang FS. Characteristics and application of Protein chip in Proteomics. World Journal of Gastroenterology 10:1431-1435, 2002. e-Pub 2002.
Abstracts
- S Neelapu FCAS. CXCR5+CD8+ T cells are localized in B cell follicles and germinal centers and exhibit regulatory and anti-tumor function. J Immunother Cancer 3:321, 2015. e-Pub 2015.
- Weng J, Chu F, Larry Kwak SSNA. Immunosuppression in the Tumor Microenvironment Session. IL-15 enhances the anti-tumor effect of human tumor antigen-specific T cells by cellular senescence delay. J Immunol 192:71.4, 2014. e-Pub 2014.
- Westin R, Chu F, Fayad L, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, Davis RE, Neelapu SS. Phase II Safety and Efficacy Study of Pidilizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. Hematol Oncol 31:150, 2013. e-Pub 2013.
- Percivalle E, Chu F, Davis RE, Neelapu SS. Effector and Regulatory T Cell Subsets in Follicular Lymphoma Tumors: Implications for Pathogenesis and Prognosis. Blood (ASH Annual Meeting Abstracts) 120:2718, 2012. e-Pub 2012.
- Chu F, Westin JR, Davis E, Neelapu SS. Immunological Effects and Predictive Gene Signatures in Patients with Relapsed Follicular Lymphoma Treated with CT-011, a Humanized Anti-PD-1 Monoclonal Antibody. Blood (ASH Annual Meeting Abstracts) 120:162, 2012. e-Pub 2012.
- Westin JR, Chu F, Rotem-Yehudar R, Neelapu S. Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts) 120:793, 2012. e-Pub 2012.
- Chu F, Ma W, Yamazaki T, Foglietta M, Nattama D, Rawal S, Wang Z, Goa Y, Orozco N, Vence L, Radvanyi L, Dong C, Davis RE, Neelapu S. PD-1+ T Cell Subsets in Follicular Lymphoma Tumor Microenvironment and Their Implications for Prognosis and Therapy. Blood (ASH Annual Meeting Abstracts) 118:2648, 2011. e-Pub 2011.
- Kannan S, Chu F, Rawal S, Foglietta M, Delgado D, Neelapu SS. Cross-Talk Between Tumor B Cells, Follicular Dendritic Cells, and Follicular Helper T Cells: Implications for Follicular Lymphoma Pathogenesis and Therapy. Blood (ASH Annual Meeting Abstracts) 118:3696, 2011. e-Pub 2011.
- Westin JR, Chu F, Foglietta M, Rotem-Yehudar R, Neelapu SS. Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. J Clin Oncol 28:15s, 2010. e-Pub 2010.
- Chu F, Foglietta M, Qin H, Sharma R, Yi Q, Rodionov G, Rotem-Yehudar R, Neelapu S. In Vitro and In Vivo Effects of CT-011, a Humanized Anti–PD-1 Monoclonal Antibody, in Combination with Rituximab against Human B-Cell Lymphomas. Blood (ASH Annual Meeting Abstracts) 114(22):302, 2009. e-Pub 2009.
Book Chapters
- F Gao FCAG. Gastrointestinal microbiology. In: The Desk Encyclopedia of Microbiology. Elsevier Pte Ltd, 37-38, 2005.
Patents
- ANTI-CD79B ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE. Patent Number: UTFC.P1405WO PCT.
Patient Reviews
CV information above last modified July 22, 2026